GLPwatch
Papers (12034)
Page 167 of 201, ranked by citation count.
- Efficacy and Safety of Dulaglutide in Type 2 Diabetes Patients in Endocrinology Clinics of Islamabad, Pakistan.
- Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
- Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply.
- Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8).
- A Case of GLP-1 Receptor Agonist-Induced Dysphoria and Aggression in a Patient With Underlying Major Depressive Disorder.
- Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few.
- Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes.
- Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- The Liraglutide-Induced Pemphigus Vulgaris: A First Case Report Highlighting Autoimmune Risks of GLP-1 Receptor Agonists.
- Dulaglutide plus dapaglifozin use until the second trimester of pregnancy in a woman with type 2 diabetes.
- The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes.
- Tirzepatide (Zepbound) for the Treatment of Obesity.
- Tirzepatide (Zepbound) for obstructive sleep apnea.
- A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes.
- A Retrospective Analysis of Liraglutide (GLP-1 Agonist) Use in a Chinchilla (<i>Chinchilla lanigera</i>) Model of Auditory Blast Injury.
- Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or Empagliflozin.
- After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
- Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications.
- Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.
- A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.
- Validation of a Questionnaire for Assessing the Emotional Impact of Treatment for Type 2 Diabetes.
- Liraglutide alleviates sepsis-associated encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis.
- The revolution of the anti-diabetic drugs in cardiology.
- Two new GLP-1 receptor agonists for diabetes.
- Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?
- AI-Based Screening for At-Risk MASLD and Advanced Fibrosis in the US Population: A Cost-Effectiveness Analysis.
- [Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system].
- Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
- Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes.
- Multiple analysis based on dual-mode anion-exchange chromatography strategy reveals significant impact of charge heterogeneity on structure and function of dulaglutide.
- MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians.
- Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.
- Is it time to REWIND the cardiorenal clock in diabetes?
- Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity.
- Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (GLP-1/GIP RA) Exposures Presenting to the Emergency Department.
- Semaglutide improves markers of cardiovascular risk in people with HIV.
- Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub-analysis of Hokkaido-TZP study data.
- A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus.
- Complementary neuroprotective effects of semaglutide and papaya in diabetic encephalopathy via antioxidant and insulin-signaling pathways.
- Effectiveness of a Psychiatrist-Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study.
- Efficacy of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus and its Impact on C-Peptide Levels.
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy.
- [Glucagon-like peptide-1 analogues: effects on body weight and glycemia].
- Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.
- Oral delivery of peptides and proteins: pharmacokinetic boundaries, negative selection, and route triage.
- Liraglutide for patients with non-alcoholic steatohepatitis.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
- Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.
- Severe Small-Bowel Obstruction in a High-Risk Patient on Long-Term Tirzepatide Therapy: A Case Report.
- Effect of Semaglutide in Individuals With Obesity or Overweight Without Diabetes.
- Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study.
- Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice.
- [Cardiovascular disease in diabetic patients: risk factors, clinical history and prevention].
- Functional enhancement of transplanted islets by Extendin-4.
- The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review.
- Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: A population-based cohort study.
- A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada.
- Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study.
- Semaglutide: A New Medical Swiss Army Knife?
- Semaglutide and Cardiovascular Outcomes. Reply.